$ANTX News
Last published 2d ago
- 2d agoANTXSTIFEL 2026 HEALTHCARE CONFERENCE - AN2 THERAPEUTICS INCEarnings Call TranscriptsStephen Willey, one of the senior biotech analysts here at Stiefel. Glad to be joined in the first session of our annual healthcare conference by CEO of AN2 Therapeutics, Eric Giesem. Eric, thank you for joining us today
- 3d agoANTXAN2 Therapeutics, Inc. (ANTX) at Guggenheim 3rd Annual Healthcare Innovation Conference - AN2 THERAPEUTICS INCEarnings Call Transcriptsconference. My name is Moritz. Our next presenting company is AN2 Therapeutics and joining us from AN2 is their CEO, Eric Giesem. So to begin with, congrats on the IND clearance. For those not familiar with the story of
- 4d agoANTXAN2 Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 4d agoANTXAN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific HighlightsBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the third quarter ended September 30, 2026 and recent business and scientific highlights. “The third quarter was marked by ...
- 2w agoANTXAN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)Business WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity
- 3w agoANTXAN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative NeoplasmsBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced
- 3w agoANTXAN2 Therapeutics to Participate at Upcoming Investor ConferencesBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced company
- 1mo agoANTXAN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSKBusiness WireFunding from Gates Foundation supports continued advancement of boron-based LeuRS inhibitors for the treatment of tuberculosis AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage pharmaceutical company focused on
- 1mo agoANTXAN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)Business WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity
- 2mo agoANTXAN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingBusiness WireAbstracts highlight epetraborole’s potential beneficial effects on hematological profile across clinical and nonclinical studies AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical stage biopharmaceutical company
- 2mo agoANTXAN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical OfficerBusiness WireDr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology AN2 Therapeutics, Inc.
- 3mo agoANTXAN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific HighlightsBusiness WireExpanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung
- 5mo agoANTXJefferies Global Healthcare Conference in New York - AN2 THERAPEUTICS INCEarnings Call TranscriptsGood afternoon, and welcome to the Jeffries Global Healthcare Conference. My name is Nick Pecora with the Jefferies Investment Banking Team, and it is my pleasure to introduce Eric Isom, CEO of AN2 Therapeutics. Thank yo
- 5mo agoANTXAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas DiseaseBusiness WireParasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans Phase 1 First-In-Human (FIH) study
- 5mo agoANTXAN2 Therapeutics to Present at 2026 Jefferies Global Healthcare ConferenceBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President
- 5mo agoANTX2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM - AN2 THERAPEUTICS INCEarnings Call TranscriptsAll right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stiefel, and glad to have with us as part of the next session, CEO of Antu Therapeutics, Eric Isom. Eric, thanks for joi
- 6mo agoANTXAN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific HighlightsBusiness WireOral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway Data expected in 2Q/2026 from two studies of oral
- 6mo agoANTXAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology ForumBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President
- 7mo agoANTXAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung DiseaseBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2
- 8mo agoANTXAN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific HighlightsBusiness WirePhase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole
- 8mo agoANTXAN2 Therapeutics Announces $40 Million Private Placement FinancingBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has entered into a
- 8mo agoANTXAN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV)Business WireSubstantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 AN2 to host webcast on
- 8mo agoANTXAN2 Therapeutics to Participate in Fireside Chat at Leerink Global Healthcare ConferenceBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President
- 1y agoANTXAN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific HighlightsBusiness WireAdvancing Phase 1 program in Chagas Disease; Phase 2 planning underway Clinical-stage M. abscessus program advancing through investigator-initiated trial (IIT) First of two boron-based oncology targets to enter
- 1y agoANTXAN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)Business WireAN2 awarded third year of funding from Gates Foundation AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today
- 1y agoANTXAN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx ConferenceBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom,
- 1y agoANTXAN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific HighlightsBusiness WireCash, cash equivalents, and investments of $71.2 million at June 30,2025 and cash runway anticipated to fund operations into 2028 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on
- 1y agoANTXAN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas DiseaseBusiness WireDNDi to share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2's oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease Startup
- 1y agoANTXAN2 Therapeutics Reports Key Insights from 200-Patient Observational Study in Acute Melioidosis, Laying Groundwork for Phase 2 Proof-of-Concept Trial of EpetraboroleBusiness WireStudy highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-concept trial for epetraborole Observational Study funded by the National Institutes of
- 1y agoANTXAN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria ConferenceBusiness WireEpetraborole's potent activity against M. abscessus supports further investigation as a potential therapy for disease with an estimated all-cause mortality of 45% AN2 Therapeutics, Inc. (NASDAQ:ANTX), a
- 1y agoANTXAN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry PipelineBusiness WireEBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease Extensive enabling NTM
- 1y agoANTXAN2 Therapeutics to Participate in Citizens JMP Life Sciences ConferenceBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom,
- 1y agoANTXAN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific HighlightsBusiness WirePhase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lung disease (TR MAC) Phase 1 first in human study of AN2-502998, under development for Chagas disease, to start mid-2025 in
- 1y agoANTXAN2 Therapeutics to Present at Leerink Partners Global Healthcare ConferenceBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom,
- 1y agoANTXAN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung DiseaseBusiness WireAN2 Selects QOL-B as New Phase 3 Primary Efficacy Endpoint Goal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potential FDA Meeting AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company
- 1y agoANTXAN2 Therapeutics to Participate at Upcoming Investor ConferencesBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company
- 1y agoANTXAN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom,
- 1y agoANTXAN2 Therapeutics to Participate at Upcoming Investor ConferencesBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company
- 2y agoANTXAN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and MalariaBusiness WireGrant from the Bill & Melinda Gates Foundation AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron
- 2y agoANTXAN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom,
- 2y agoANTXAN2 Therapeutics Adopts Limited Duration Stockholder Rights PlanBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a
- 2y agoANTXAN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific HighlightsBusiness WireCash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company focused on
- 2y agoANTXAN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung DiseaseBusiness WireEBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron chemistry platform and
- 2y agoANTXAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsBusiness WirePlan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary
- 2y agoANTXAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsBusiness WirePhase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of
- 2y agoVBIVVIRANTXBrii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial ResultsPR NewswireBrii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health...
- 2y agoANTXAN2 Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the FirmGlobeNewswireBOSTON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating AN2 Therapeutics, Inc. (NASDAQ:ANTX) for potential securities law violations. Investors who have lost money in their AN2 Therapeutics, Inc.
- 2y agoANTXAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseBusiness Wire-Enrolled patients allowed to continue on study- AN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases
- 2y agoANTXAN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences ConferenceBusiness WireAN2 Therapeutics, Inc. (NASDAQ:ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric
- 3y agoANTXAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsBusiness WireEnrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease On track to announce Phase 2 clinical data summer